"We didn't start with the easy parts."
The two hardest problems in patent reading, and the four risks that actually keep pharma IP teams up at night — solved first.
"Ask any experienced patent reader what actually eats their week."
It's rarely the filing itself — it's finding the one independent claim inside an application that cross-references hundreds of other patents, and it's manually checking new design publications against a client portfolio one journal at a time.
Both are expensive precisely because they consume specialist hours on work that doesn't require specialist judgment — which is exactly why Novo59 was built to solve these two first, before anything else.
Four reasons this isn't just about speed.
"Your IP team doesn't lie awake worrying about processing time. They worry about the launch that gets blocked, the pipeline move they missed, and the R&D budget spent on something already claimed."
Freedom-to-Operate (FTO)
FTO review is, and should remain, a human legal judgment call. What slows that judgment down today is finding the right claims across hundreds of filings. Novo59 doesn't make the FTO determination — it surfaces every relevant independent claim, patent family, and chemical structure your team needs, so your lawyers make that call on complete, structured data in a fraction of the time it takes to assemble it manually.
Competitor Pipeline Tracking
Patent filings are often the first public trace of what a rival is developing — long before any press release. Automated categorization and family mapping turn scattered filings into a structured, searchable view of competitor activity, so your team catches the signal early instead of reading about it after the fact.
Patent Cliff Protection
Generic entry timing is a multi-million-dollar decision, and it depends on knowing the true expiry of a patent family — including any continuations or related filings that extend protection. Novo59's family mapping gives you the complete picture, not just the headline patent.
R&D Prior Art Overlaps
A chemist can spend months on a compound already covered by an existing patent. With IUPAC and SMILES extraction tied directly to independent claims, your R&D and IP teams can check structured chemical data against prior claims — not rely on manual claim-reading to catch an overlap.
Why Design Matching is its Own Solution
Design patent work runs on a different clock than pharma: journals publish continuously, and a missed match means a missed opportunity to advise a client before someone else moves. Novo59's Track A exists because no other tool in the Indian market processes design-patent journal matching at this depth — it's not an add-on to a generic patent tool, it's a dedicated solution for a workflow that's still manual industry-wide.
Give your experts back their 40%. Let Novo59 handle the 60% that was never worth their time.
The launch you're planning, the pipeline you're watching, the R&D dollars you don't want to waste — all of it depends on having the right patent data in front of your experts, fast enough to matter.